Ponatinib hydrochloride (HCl) API, a tyrosine kinase inhibitor, has emerged as a powerful tool in treating certain types of leukemia. However, its journey since FDA approval has been marked by both promise and controversy. While clinical trials demonstrated its efficacy, real-world evidence (RWE) is crucial for understanding its effectiveness and safety in everyday clinical practice.
The...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian